RE: FN Clueless27 Jun 2022 09:11
he guys, i totally understand displeasure but I have to be honest. I don't see any point here where Geremy or GDBY has completely developed the company away from its actual focus - CBD. Just look at the FSA nonsense. It's not GDBY's fault if it takes the authorities 2 years to find a clear line. And even now, the FSA is not in a position to implement the rules it has defined itself and to remove all products not on the list from the market as soon as possible.
GDBY itself is doing everything to complete the process. As far as I know, the FSA has everything it needs to complete the final authorisation.
During this time, the company has been set up so that they can continue to do business. In the last three months, the focus has clearly been on developing the existing clinic network towards blood testing. The process of connecting pharmacies was optimised.
If you were to look in detail at your investment, you would have noticed that GDBY seems to have implemented pilot projects with many smaller networks (10-25 pharmacies) in the last 3 months with 1-2 sites. A Geremy or Marc do not throw around 450-600 locations by the end of Q3 for nothing because as you all know GDBY is pretty conservative in forecastings.
I know it sounds stupid, but patience is still needed. If by the end of Q3, the pharmacy count does not reach at least 400-450, one should think twice.
And the listing on the LSE or a higher exchange than AQSE in the UK will only be done once the de-listing in Canada is done and GDBY has a GB ISIN. That can't happen before September. It needs approval at the AGM in early August. From then on, maybe another 4-6 weeks until this is fully implemented. As far as I know, the up-listing on the AIM/LSE costs 500k pounds.
So clench your cheeks and think positive.
Sign In
Follow the stocks
